Organon & Co.
OGN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821825
In the last 90 days, Organon & Co. insiders filed 0 open-market purchases and 1 sale; 636 institutions reported holding it in 13F filings for Q2 2026, worth $2.92B in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Organon & Co. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 720 | 10 | 727 | +17 |
| Shares | 199.3M | 473.4K | 198.5M | −416.2K (−0.2%) |
| Value | $3.75B | $8.93M | $4.11B | +$368.8M (+9.9%) |
10 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (84)
Institutions that held Organon & Co. at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (67)
Institutions that held Organon & Co. at the end of Q1 2024 and filed for Q2 2024 without it.
Not filed for Q2 2024 yet (10)
Institutions that held Organon & Co. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Credit Suisse AG | 415,300 | $7.81M |
| Benedetti & Gucer, Inc. | 20,245 | $381.0K |
| Shell Asset Management Co | 15,674 | $324.0K |
| Oracle Alpha Inc. | 15,371 | $289.0K |
| Highlander Capital Management, LLC | 5,232 | $98.4K |
| Cambridge Trust Co | 1,155 | $21.7K |
| Norwood Financial Corp | 261 | $4.90K |
| Pflug Koory, LLC | 64 | $1.20K |
| FSA Wealth Management LLC | 63 | $1.18K |
| Retirement Group, LLC | 11 | $207 |